Clinical Trial

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-05-19; most recent amendment 2025-05-07.
Status change: Not Yet Recruiting → Recruiting 2024-03-15
Trial Details
NCT Number NCT05868733
Lead Sponsor International AIDS Vaccine Initiative
Collaborators: Coalition for Epidemic Preparedness Innovations
Conditions Lassa Fever
Enrollment 612 participants
Start Date 2024-03-06
Primary Completion 2026-12 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-05-11